What is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for Genmab A/S from $0.44 to $0.50, maintaining a "Buy" rating with a price target of $40.00.
• Genmab A/S reported an EPS of $0.54 for the last quarter, exceeding expectations of $0.39, and has set a full-year EPS guidance of $1.45.
• Institutional investors have shown significant interest, with several funds increasing their holdings in Genmab A/S by over 100% in recent quarters.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 EPS estimates for Genmab A/S in a research note issued to investors on Wednesday, October 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.50 per share for the quarter, up from their prior estimate of $0.44. HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's FY2025 earnings at $1.78 EPS and Q1 2026 earnings at $0.36 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen raised shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, September 26th. Weiss Ratings reissued a "hold (c)" rating on shares of Genmab A/S in a report on Wednesday, October 8th. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Zacks Research raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Finally, Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

Genmab A/S Trading Down 0.1%

Shares of GMAB stock opened at $32.72 on Thursday. The firm has a market capitalization of $21.01 billion, a P/E ratio of 16.44, a price-to-earnings-growth ratio of 1.85 and a beta of 0.98. The firm's fifty day simple moving average is $27.51 and its 200 day simple moving average is $23.13. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $33.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Orbis Allan Gray Ltd lifted its position in Genmab A/S by 102.8% during the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock valued at $111,816,000 after purchasing an additional 2,895,179 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company's stock valued at $71,367,000 after purchasing an additional 2,084,966 shares during the period. Cubist Systematic Strategies LLC lifted its position in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company's stock valued at $24,634,000 after purchasing an additional 665,893 shares during the period. Russell Investments Group Ltd. raised its position in shares of Genmab A/S by 111.5% in the 1st quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company's stock valued at $21,149,000 after acquiring an additional 569,345 shares during the period. Finally, ABC Arbitrage SA acquired a new stake in shares of Genmab A/S in the 2nd quarter valued at approximately $9,236,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.